2012
Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
Ruger JP, Chawarski M, Mazlan M, Ng N, Schottenfeld R. Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia. PLOS ONE 2012, 7: e50673. PMID: 23226534, PMCID: PMC3514172, DOI: 10.1371/journal.pone.0050673.Peer-Reviewed Original ResearchConceptsHeroin dependenceCost-effectiveness ratioSecondary outcomesOutcome measuresDrug usePlacebo-controlled clinical trialFirst heroin useIncremental cost-effectiveness ratioSocietal costsInjection drug useSecondary outcome measuresPrimary outcome measureIllicit opiate useIncremental treatment costNaltrexone treatmentPrimary outcomeMedication costsPlacebo interventionClinical trialsHeroin abstinenceOpiate useHeroin useBuprenorphineTreatment retentionNaltrexone
2008
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial
Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. The Lancet 2008, 371: 2192-2200. PMID: 18586174, PMCID: PMC4041792, DOI: 10.1016/s0140-6736(08)60954-x.Peer-Reviewed Original ResearchConceptsFirst heroin useHIV risk behaviorsHeroin dependenceHeroin useHeroin relapseMaintenance treatmentHeroin abstinenceDrug counsellingComputer-generated randomisation sequenceRisk behaviorsEffective public health approachConsecutive daysInterim safety analysisOutpatient research clinicPlacebo-controlled trialEfficacy of naltrexoneHeroin-dependent patientsMonths of enrollmentPrevention of relapseWorldwide health priorityPublic health approachRandomisation sequencePrimary outcomeHIV transmissionHIV risk